DGAP-News

True Leaf Announces Private Placement

DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Capital Increase/Regulatory Approval True Leaf Announces Private Placement 03.05.2017 / 13:10 The issuer is solely responsible for the content of this announcement. For Immediate Release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

True Leaf Announces Private Placement

Vancouver, BC, May 3, 2017 - True Leaf Medicine International Ltd. (the "Company") (MJ: CSE)(TLA: FSE) is pleased to announce that it intends to complete a non-brokered private placement of units of the company (each, a "Unit") at a price of C$0.30 per Unit, with each Unit being comprised of one common share of the Company (a "Common Share") and one warrant exercisable into one Common Share at an exercise price of $0.45 per Common Share for a period of 24 months (the "Offering") for aggregate gross proceeds of up to C$3,000,000.

All or a portion of the Offering may be completed pursuant to Multilateral CSA Notice 45-318 Prospectus Exemption for Certain Distributions through an Investment Dealer ("CSA 45-318") and the corresponding instruments, orders and rules implementing CSA 45-318 in the participating jurisdictions (collectively with CSA 45-318, the "Investment Dealer Exemption"). In order for the Company to be able to rely on the Investment Dealer Exemption, each subscriber must purchase the Units as principal and obtain advice regarding the suitability of the investment from a person who is registered as an investment dealer in the jurisdiction in which the subscriber is resident.

The Company intends to use the proceeds of the Offering as follows:

True Leaf Medicine Inc.: Federal Medicinal Cannabis License applicant under the 'ACMPR'


Property Expansion $650,000

Expert Consulting $250,000

Capital Asset $250,000

Legal Fees $175,000

True Leaf Pet


Marketing $650,000

Inventory Expansion $350,000

General Admin $250,000

Legal fees $75,000

True Leaf Pet Europe